Sat Kartar Life Ltd

Sat Kartar Life Ltd (SKL) is a micro-cap Healthcare company valued at ₹19 crore operating in Pharmaceuticals & Biotechnology on the NSE and BSE.

Recent price move

Sat Kartar Life Ltd last traded at ₹15, unchanged on the day.

Recent developments

2026-09-07: The DocStoX score remained unchanged at 6.8, with the verdict of hold in place. 2026-08-15: The score was last updated to 6.8, reflecting no significant change in the company's fundamentals.

Financial performance

The company's business is improving, with annual revenue rising 10.0% and net profit growing 37.3%. However, the latest quarter saw revenue fall 11.5% compared to the same quarter a year earlier, while net profit surged 75.0% from zero to ₹1 crore. Margins have improved, with the net profit margin rising 0.6 percentage points to 3.0%, but returns remain low, with return on equity at 4.2% and return on capital employed at 3.8%.

Valuation multiples

The stock trades at 2.4 times earnings, a discount to the Healthcare median of 32.4, 3.03 times book value. It yields 0.5%.

Things to watch

The company is not paying dividends despite reporting profits, which could signal financial pressure or strategic choices. The low interest coverage ratio and the possibility of capitalizing interest costs raise concerns about debt management. The stock is trading 5.0% below its 52-week high, indicating potential investor caution.

Where it stands

The DocStoX verdict of hold follows from the company's mixed performance, with strong profit growth but weak returns and low interest coverage. The most critical factor is the lack of dividend payouts despite reported profits, which may signal financial strain or poor capital allocation.

Summarised by DocStoX's model on 2026-09-08 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.